David Liu (courtesy Broad Institute)

They’re go­ing for it: David Liu’s pre­clin­i­cal biotech shoots for a (maybe $200M) IPO

Can a pre­clin­i­cal biotech with grand am­bi­tions, a star sci­en­tif­ic founder and en­thu­si­as­tic back­ers with deep pock­ets fly a big IPO against the gale force …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.